JP2024540994A5 - - Google Patents
Info
- Publication number
- JP2024540994A5 JP2024540994A5 JP2024524371A JP2024524371A JP2024540994A5 JP 2024540994 A5 JP2024540994 A5 JP 2024540994A5 JP 2024524371 A JP2024524371 A JP 2024524371A JP 2024524371 A JP2024524371 A JP 2024524371A JP 2024540994 A5 JP2024540994 A5 JP 2024540994A5
- Authority
- JP
- Japan
- Prior art keywords
- dna
- cytoplasmic
- inhibitor
- sensing inhibitor
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203451P | 2021-07-23 | 2021-07-23 | |
| US63/203,451 | 2021-07-23 | ||
| PCT/US2022/074084 WO2023004437A1 (en) | 2021-07-23 | 2022-07-22 | Method of enhancing gene therapy by targeting cgas-sting pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540994A JP2024540994A (ja) | 2024-11-06 |
| JP2024540994A5 true JP2024540994A5 (OSRAM) | 2025-07-25 |
Family
ID=84980517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524371A Pending JP2024540994A (ja) | 2021-07-23 | 2022-07-22 | 非ウイルス性ｄｎａ送達のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240350667A1 (OSRAM) |
| EP (1) | EP4373946A4 (OSRAM) |
| JP (1) | JP2024540994A (OSRAM) |
| KR (1) | KR20240083170A (OSRAM) |
| CN (1) | CN117980487A (OSRAM) |
| AU (1) | AU2022316228A1 (OSRAM) |
| CA (1) | CA3230386A1 (OSRAM) |
| CO (1) | CO2024002065A2 (OSRAM) |
| IL (1) | IL311167A (OSRAM) |
| WO (1) | WO2023004437A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025531749A (ja) * | 2022-09-09 | 2025-09-25 | スパーク セラピューティクス インコーポレイテッド | ピペラジン化合物 |
| WO2024067560A1 (zh) * | 2022-09-26 | 2024-04-04 | 中国药科大学 | 磺酰胺类化合物及其医药用途 |
| WO2025265081A1 (en) * | 2024-06-21 | 2025-12-26 | Stylus Medicine, Inc. | cGAS-STING PATHWAY INHIBITORS AND USES THEREOF |
| CN118908937B (zh) * | 2024-07-10 | 2025-07-15 | 中山大学中山眼科中心 | 一种具有sting蛋白降解作用的化合物及其制备方法和用途 |
| CN119185549B (zh) * | 2024-10-25 | 2025-09-02 | 四川大学华西医院 | Sting抑制剂在制备治疗或预防心脏骤停后综合征药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011127255A1 (en) * | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
| PT2934598T (pt) * | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| MX2021008874A (es) * | 2019-01-24 | 2021-08-19 | Generation Bio Co | Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. |
| EP4061403A4 (en) * | 2019-11-19 | 2023-12-27 | Spark Therapeutics, Inc. | Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders |
-
2022
- 2022-07-22 JP JP2024524371A patent/JP2024540994A/ja active Pending
- 2022-07-22 KR KR1020247006154A patent/KR20240083170A/ko active Pending
- 2022-07-22 US US18/685,681 patent/US20240350667A1/en active Pending
- 2022-07-22 EP EP22846872.4A patent/EP4373946A4/en active Pending
- 2022-07-22 IL IL311167A patent/IL311167A/en unknown
- 2022-07-22 CA CA3230386A patent/CA3230386A1/en active Pending
- 2022-07-22 AU AU2022316228A patent/AU2022316228A1/en active Pending
- 2022-07-22 WO PCT/US2022/074084 patent/WO2023004437A1/en not_active Ceased
- 2022-07-22 CN CN202280063892.2A patent/CN117980487A/zh active Pending
-
2024
- 2024-02-23 CO CONC2024/0002065A patent/CO2024002065A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10709797B2 (en) | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy | |
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| US8853177B2 (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | |
| CN103333890B (zh) | 治疗乙型病毒性肝炎的rna干扰制剂 | |
| JP2019532080A5 (OSRAM) | ||
| CN104220599A (zh) | 人工核酸分子 | |
| US10227302B2 (en) | Ionizable cationic lipid for RNA delivery | |
| ES2743600T3 (es) | Métodos de tratamiento de los trastornos inflamatorios vasculares | |
| TW201408309A (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| EP3898942A1 (en) | Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| US20220305118A1 (en) | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines | |
| US11564884B2 (en) | Cationic block polymer micelles for delivery of biological agents | |
| AU2016300141B2 (en) | Therapeutic oligonucleotides | |
| WO2018193902A1 (ja) | マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果 | |
| KR20110139743A (ko) | 모균증 및 다른 진균 질환의 치료를 위한 백신 조성물 및 방법 | |
| EP3329004A1 (en) | Therapeutic oligonucleotides | |
| WO2013088853A1 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| WO2014195693A1 (en) | Prevention and treatment of atrial fibrillation | |
| US20210198629A1 (en) | Compositions and methods for increasing beiging of white adipose tissue | |
| WO2023237726A1 (en) | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| RU2024104579A (ru) | Способы и композиция для невирусной доставки днк | |
| WO2026060527A1 (en) | Methods for inhibiting adenylate cyclase type 9 (ac9) and uses thereof | |
| WO2023215716A1 (en) | Compositions and methods for treatment of cancer |